IP Library › Patent Application 13374328
Patent Application
App. No. 13/374,328

Bromelain proteinases (Bromelainases) as chemotherapeutic agents in treating and/or preventing various types of cancer in a mammal

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/374,328
Abstract

A method for treating and/or preventing various types of human cancer and neoplastic diseases which is comprised of the administration thereto of an effective amount of Bromelain extract derived from Ananas Comosus and such proteins as ananase, bromelain, comosain, extranase, Inflamen, traumanase, and/or a mixture thereof.

Claims (6)

1 . The present discovery and invention relates to a method for treating and/or preventing various types of cancerous disease in a mammal, which is comprised of the administration thereto of an effective amount of Bromelain proteins, enzyme complex derived from Ananas Comosus.

2 . The method of claim 1 : wherein the mammal is human.

3 . The method of claim 1 : Wherein the bromelain proteinases mixture thereof is administered in the form of pharmaceutical composition containing an effective amount of bromelain and pharmaceutically acceptable excipients, carriers or dilutents.

4 . The method of claim 1 , wherein the effective amount of the bromelain proteinases or a mixture thereof ranges from 0.1 to 500 mg/kg of body weight/day.

5 . The method of claim 1 , the bromelain proteins derived from Ananas Comosus and with a solvent selected from the group consisting of water, a low alcohol and an aqueous alkali- or alkaline earth-metal hydroxide solution and/or an acid solution.

6 . The method of claim 3 , wherein the bromelain proteins have cytotoxic (through T-cell), anti-platelet aggregation (anti-metastasis effect), anti-inflammation, and anti-tumor-genesis (anti-proliferation and tumor necrotizing factor) effect against various types of cancer cell lines, in animal and human experiments both in vitro and in vivo, such as breast, colon, lung, ovarian, cervical, and uterine cancer.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAMES PREVIOUSLY RECORDED AT REEL: 030503 FRAME: 0704. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Nov 22, 2017
From: LIAO, ALEX BISMARK; LIAO, AUSTIN LEWIS; LIAO, BENEDICT SCHUE; LIAO, BURTON ARTHUR; LI-LIAO, JUDY FU-CHUAN; LIAO, LUDWIG SCHUE; LEO, STANLEY; LIAO-CHEN, SU-LIEN; LIAO-NIENG, SUSAN JOAN; TUNG-LIAO, SUSAN SU-HSIN
To: GARFIELD HEMATOLOGY AND ONCOLOGY CONSULTANTS MEDICAL GROUP, INC.
Reel/Frame 044510/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2013
From: LIAO, ALEX BISMARK, MR.; LIAO, AUSTIN LEWIS, MR.; LIAO, BENEDICT SCHUE, MR.; LIAO, BURTON ARTHUR, MR.; LIAO, EDWARD REGEAN, MR.; LI-LIAO, JUDY FU-CHUAN, MS.; LIAO, JUSTIN, MR.; LIAO, LILY, MS.; LIAO, LUDWIG SCHUE, MR.; LIAO, ROBERT BERNARD, MR.; LEO, STANLEY, MR.; LIAO-CHEN, SU-LIEN, SM; LIAO-NIENG, SUSAN JOAN, MS.; TUNG-LIAO, SUSAN SU-HSIN, MS.
To: GARFIELD HEMATOLOGY AND ONCOLOGY CONSULTANTS MEDICAL GROUP, INC.
Reel/Frame 030503/0704 →